内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果

2018-06-26 MedSci MedSci原创

1型糖尿病empagliflozin辅助治疗
关注

勃林格殷格翰公司和礼来公司今天宣布EAS​​E III期随机对照试验的研究结果显示，empagliflozin联合胰岛素治疗在成人1型糖尿病中的应用符合主要终点。所有研究剂量的empagliflozin（2.5、10和25 mg）均符合主要疗效终点。

目前1型糖尿病影响美国130万成人和全球约3000万成年人。它是一种自身免疫性疾病，患者免疫系统攻击胰腺中的胰岛细胞，并最终破坏它们制造胰岛素的能力，身体不产生足够量的胰岛素，因此需要终身每日胰岛素给药来调节血糖。对于一些患有1型糖尿病的人来说，单独使用胰岛素来管理血糖水平可能具有挑战性。1型糖尿病患者还面临视力下降、心脏病、肾脏疾病和截肢等并发症的风险。尽管胰岛素治疗和患者护理方面取得了显著进展，但在美国，1型糖尿病患者中不到三分之一的患者一直保持着目标血糖水平。

勃林格殷格翰公司和礼来公司今天宣布EAS​​E III期随机对照试验的研究结果显示，empagliflozin联合胰岛素治疗在成人1型糖尿病中的应用符合主要终点。所有研究剂量的empagliflozin（2.5、10和25 mg）均符合主要疗效终点。


原始出处：

http://www.firstwordpharma.com/node/1574468#axzz5JX2NWGqk

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954276, encodeId=f41b19542e600, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Apr 09 01:45:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749980, encodeId=89291e499807e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 16:45:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028055, encodeId=becf2028055e8, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 02 04:45:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039502, encodeId=d6472039502c4, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3611, encryptionId=636836118c, topicName=Boehringer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed Dec 26 07:45:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021631, encodeId=825b202163160, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Oct 09 16:45:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2019-04-09 仁医06

    #empagliflozin#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1954276, encodeId=f41b19542e600, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Apr 09 01:45:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749980, encodeId=89291e499807e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 16:45:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028055, encodeId=becf2028055e8, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 02 04:45:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039502, encodeId=d6472039502c4, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3611, encryptionId=636836118c, topicName=Boehringer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed Dec 26 07:45:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021631, encodeId=825b202163160, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Oct 09 16:45:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2019-05-06 baoya

    #胰岛#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1954276, encodeId=f41b19542e600, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Apr 09 01:45:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749980, encodeId=89291e499807e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 16:45:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028055, encodeId=becf2028055e8, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 02 04:45:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039502, encodeId=d6472039502c4, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3611, encryptionId=636836118c, topicName=Boehringer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed Dec 26 07:45:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021631, encodeId=825b202163160, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Oct 09 16:45:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2019-01-02 syscxl

    #Lilly#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1954276, encodeId=f41b19542e600, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Apr 09 01:45:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749980, encodeId=89291e499807e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 16:45:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028055, encodeId=becf2028055e8, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 02 04:45:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039502, encodeId=d6472039502c4, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3611, encryptionId=636836118c, topicName=Boehringer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed Dec 26 07:45:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021631, encodeId=825b202163160, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Oct 09 16:45:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2018-12-26 12498fa0m11暂无昵称

    #Boehringer#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1954276, encodeId=f41b19542e600, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Apr 09 01:45:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749980, encodeId=89291e499807e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 16:45:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028055, encodeId=becf2028055e8, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 02 04:45:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039502, encodeId=d6472039502c4, content=<a href='/topic/show?id=636836118c' target=_blank style='color:#2F92EE;'>#Boehringer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3611, encryptionId=636836118c, topicName=Boehringer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Wed Dec 26 07:45:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021631, encodeId=825b202163160, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Oct 09 16:45:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2018-10-09 12498c32m68暂无昵称

    #GER#

    0

相关资讯

Diabetologia：1型糖尿病遗传易感性儿童的血液转录组学中肠道病毒相关的变化

近日，国际杂志 《Diabetologia》上在线发表一项关于1型糖尿病遗传易感性儿童的血液转录组学中肠道病毒相关的变化的研究。 多项研究表明肠道病毒感染与1型糖尿病的发展有关，但对有发生1型糖尿病风险的儿童肠道病毒诱导的反应知之甚少。研究人员的目标是使用全基因转录组学数据来描述患有1型糖尿病遗传易感性的儿童的全血样品中肠道病毒相关的变化的特征。 研究人员从28对患1型糖尿病的风险增加

Diabetes Care：与1型糖尿病病程和血管并发症相关的认知功能缺损！

由此可见，1型糖尿病患者和2型糖尿病患者总体认知能力均明显低于对照组。此外，在50岁以上的1型糖尿病患者中，观察到了并发症与认知之间的关系。虽然两组糖尿病患者表现出相似的赤字模式，但其潜在机制可能不同。当前，1型糖尿病患者的寿命延长，应努力评估认知和识别可改变的行为，以减缓下降。

Diabetologia：在1型糖尿病小鼠模型中膜联蛋白A1通过恢复Akt信号传导来减弱微血管并发症

近日，国际杂志 《Diabetologia》上在线发表一项关于在1型糖尿病小鼠模型中膜联蛋白A1通过恢复Akt信号传导来减弱微血管并发症的研究。 心脏和肾脏中的微血管并发症与炎症的整体升高密切相关。膜联蛋白A1（ANXA1）是限制和消除炎症的内源性抗炎分子。在这项研究中，研究人员使用a bedside to bench approach方法来调查：（1）1型糖尿病患者的ANXA1水平；（2）

Cell Rep：新技术成功治疗小鼠糖尿病！

近日，科学家利用组织工程学方法在实验室中对人类胰岛细胞进行改造，使其能够形成循环系统，并分泌胰岛素等激素，还能成功治疗小鼠突发的1型糖尿病。这项研究已发表在5月8日的《Cell Reports》上，由美国辛辛那提儿童医院医疗中心和日本横滨市立大学(YCU)合作完成。

卡介苗可长期改善1型糖尿病患者的血糖

近一个世纪来，为防止结核病的发生，卡介苗已有30多年的应用历史，其目的是促进细胞因子--肿瘤坏死因子（TNF）的产生，TNF可帮助消除攻击个体胰岛beta细胞的的自身反应性T细胞

Diabetologia：持久的HbA1C改善很少发生1型糖尿病5年后及其临床意义

近日，国际杂志 《Diabetologia》上在线发表一项关于持久的HbA1C改善很少发生1型糖尿病5年后及其临床意义：一个有关早期，针对性和积极的干预下诊断争论的研究。 研究人员的目标是探索1型糖尿病患者是否有HbA1C “跟踪”现象，诊断后多长时间跟踪变得稳定，以及是否性别和年龄会在跟踪诊断的上有效果。 研究人员健康改善网络（THIN）数据库中共确认了1995年1月1日至2015年